Esperion Therapeutics (NASDAQ:ESPR) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($3.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.08) by ($1.42), MarketWatch Earnings reports. The company had revenue of $8.00 million for the quarter, compared to analyst estimates of $34.28 million. Esperion Therapeutics had a negative net margin of 46.15% and a negative return on equity of 629.88%. Esperion Therapeutics’s revenue for the quarter was up 344.4% on a year-over-year basis. During the same quarter last year, the firm posted ($2.84) EPS.
Shares of ESPR stock opened at $25.59 on Wednesday. The company’s fifty day simple moving average is $27.84 and its two-hundred day simple moving average is $28.91. Esperion Therapeutics has a 1 year low of $23.90 and a 1 year high of $53.73. The stock has a market capitalization of $720.51 million, a price-to-earnings ratio of -6.65 and a beta of 1.48.
ESPR has been the subject of a number of analyst reports. Jefferies Financial Group downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the company from $40.00 to $30.00 in a research note on Friday, February 12th. Bank of America downgraded Esperion Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the stock from $52.00 to $35.00 in a research note on Friday, January 15th. The Goldman Sachs Group downgraded Esperion Therapeutics from a “neutral” rating to a “sell” rating and cut their target price for the stock from $44.00 to $24.00 in a research note on Tuesday, February 9th. JMP Securities cut their target price on Esperion Therapeutics from $191.00 to $111.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, Needham & Company LLC cut their target price on Esperion Therapeutics from $150.00 to $134.00 and set a “strong-buy” rating on the stock in a research note on Wednesday, March 3rd. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $51.09.
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
Read More: What is a short straddle?
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.